Aytu Biopharma, Inc.
AYTU
$1.27
$0.010.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.22M | 16.57M | 17.98M | 17.99M | 18.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.22M | 16.57M | 17.98M | 17.99M | 18.75M |
| Cost of Revenue | 5.44M | 4.59M | 5.34M | 6.30M | 4.15M |
| Gross Profit | 10.79M | 11.99M | 12.64M | 11.69M | 14.60M |
| SG&A Expenses | 9.72M | 10.78M | 11.09M | 11.99M | 10.02M |
| Depreciation & Amortization | 921.00K | 921.00K | 1.30M | 1.30M | 918.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.60M | 16.72M | 18.78M | 20.21M | 15.60M |
| Operating Income | -378.00K | -146.00K | -799.00K | -2.22M | 3.15M |
| Income Before Tax | 382.00K | 1.50M | -3.92M | -2.64M | 1.40M |
| Income Tax Expenses | -283.00K | 405.00K | 695.00K | 245.00K | 780.00K |
| Earnings from Continuing Operations | 665.00K | 1.09M | -4.62M | -2.89M | 619.00K |
| Earnings from Discontinued Operations | 123.00K | 381.00K | -- | -- | -839.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 788.00K | 1.47M | -4.62M | -2.89M | -220.00K |
| EBIT | -378.00K | -146.00K | -799.00K | -2.22M | 3.15M |
| EBITDA | 961.00K | 1.28M | 1.15M | -301.00K | 4.94M |
| EPS Basic | 0.13 | 0.24 | -0.82 | -0.52 | -0.04 |
| Normalized Basic EPS | 0.17 | 0.24 | 0.00 | -0.27 | 0.16 |
| EPS Diluted | -0.26 | -0.16 | -0.82 | -0.52 | -0.04 |
| Normalized Diluted EPS | 0.13 | 0.16 | 0.00 | -0.27 | 0.16 |
| Average Basic Shares Outstanding | 6.13M | 6.07M | 5.62M | 5.53M | 5.52M |
| Average Diluted Shares Outstanding | 8.49M | 9.10M | 5.62M | 5.53M | 5.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
